# A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT07306832** · PHASE1 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Pivekimab Sunirine

## Key facts

- **NCT ID:** NCT07306832
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306832, "A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07306832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*